We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
201
Regenxbio
RGNX
$620M
$799K 0.03%
21,700
– –
IMGN
202
DELISTED
Immunogen Inc
IMGN
$774K 0.03%
168,190
– –
PBYI icon
203
Puma Biotechnology
PBYI
$404M
$744K 0.03%
71,340
– –
CDTX
204
DELISTED
Cidara Therapeutics
CDTX
$720K 0.03%
9,763
– –
MOR
205
DELISTED
MorphoSys AG American Depositary Shares
MOR
$614K 0.02%
19,390
– –
NHI icon
206
National Health Investors
NHI
$3.72B
$610K 0.02%
10,038
– –
CHCT
207
Community Healthcare Trust
CHCT
$523M
$609K 0.02%
14,900
– –
MTEM
208
DELISTED
Molecular Templates, Inc.
MTEM
$583K 0.02%
2,821
– –
GMAB icon
209
Genmab
GMAB
$17.7B
$560K 0.02%
16,520
-131,628
-89% -$3.59M
SPPI
210
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$388K 0.01%
114,670
– –
TPTX
211
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$367K 0.01%
5,677
– –
CYH icon
212
Community Health Systems
CYH
$393M
$354K 0.01%
117,735
– –
WHWK
213
Whitehawk Therapeutics
WHWK
$190M
$322K 0.01%
17,170
– –
CLSD
214
DELISTED
Clearside Biomedical
CLSD
$311K 0.01%
11,022
– –
CBAY
215
DELISTED
Cymabay Therapeutics
CBAY
$307K 0.01%
88,102
– –
ORKA
216
Oruka Therapeutics
ORKA
$5.82B
$215K 0.01%
2,705
-301
-10% -$19.7K
TTPH
217
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$108K ﹤0.01%
42,965
– –
ALR
218
DELISTED
AlerisLife Inc
ALR
$95K ﹤0.01%
24,237
– –
CLDX icon
219
Celldex Therapeutics
CLDX
$2.99B
$92K ﹤0.01%
7,053
– –
MNK
220
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$88K ﹤0.01%
32,980
– –
BLCM
221
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$45K ﹤0.01%
6,000
– –
HQY icon
222
HealthEquity
HQY
$8.41B
– –
-27,310
Closed -$1.38M
MRUS
223
DELISTED
Merus
MRUS
– –
-21,215
Closed -$257K
VIE
224
DELISTED
Viela Bio, Inc. Common Stock
VIE
– –
-500
Closed -$19K
AGN
225
DELISTED
Allergan plc
AGN
– –
-157,981
Closed -$28M
6 7 8
9
10

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.